--- title: "Niche U.S. Equities Face Strategic Shifts From Aviation Buyouts to Biotech Pipeline Advances" type: "News" locale: "en" url: "https://longbridge.com/en/news/296906244.md" description: "A diverse group of U.S.-listed assets covering private aviation, biotech, and thematic ETFs is navigating a wave of business reorganizations. FlyUSA raised its full-year forecast, 10x Genomics completed a recent acquisition, and institutional funds are reassessing allocations." datetime: "2026-08-25T11:33:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296906244.md) - [en](https://longbridge.com/en/news/296906244.md) - [zh-HK](https://longbridge.com/zh-HK/news/296906244.md) generator: "portal-rs" --- # Niche U.S. Equities Face Strategic Shifts From Aviation Buyouts to Biotech Pipeline Advances A group of U.S.-listed equities spanning diverse sectors from private aviation and biotechnology to hardware manufacturing and emerging market ETFs is navigating a complex landscape of strategic realignments and market shifts, according to recent regulatory filings and industry data. ### FlyUSA (FLY.US) FlyUSA expects its full-year 2025 total revenue to land between USD 75 million and USD 80 million, a figure the company is targeting to reflect a doubling of revenue year-over-year. The firm completed the acquisition of TRYP Air Charter in May 2025 and has expanded its national workforce to 110 employees, according to people familiar with the matter. As of June 2025, its fleet managed 20 aircraft serving over 1,000 customers, with recent stock performance supported by this expansion pace. ### VanEck Vietnam ETF (VNM.US) The exchange-traded fund tracking Vietnamese companies has seen elevated trading activity recently. Trading data from late August 2026 showed daily volume exceeding 530,000 shares, significantly above its average daily volume of roughly 366,000 shares. As of August 2026, the fund had 103 institutional owners and shareholders, with recent price action reflecting the volatility of emerging market capital flows. ### T-REX 2X Long AXTI Daily Target ETF (AXTU.US) Tuttle Capital Management formally launched the product in May 2026. Designed to provide 200% of the daily price movement of AXT, Inc., the ETF is positioned as a short-term tactical instrument requiring daily rebalancing. Industry insiders note that inflows into such leveraged tools are highly correlated with the short-term volatility of the underlying semiconductor materials sector. ### Arcturus Therapeutics (ARCT.US) The RNA medicines biotech company is making headway in vaccine commercialization. Following its COVID-19 vaccine authorization in Japan in 2023, the product was officially authorized in the EU in 2025. The company is advancing its clinical pipeline for cystic fibrosis (ARCT-032), and the stock's recent performance partially reflects the market's pricing of its mRNA platform's commercial potential. ### Sibanye Stillwater (SBSW.US) As one of the world's largest producers of platinum group metals (PGMs), Sibanye Stillwater's core revenue remains heavily dependent on the mining and sale of platinum, palladium, and rhodium used in auto catalysts. The company continues to maintain operations across South Africa and international markets amid macroeconomic and industrial demand shifts. The stock has faced some cyclical pressure this year due to fluctuating precious metal prices. ### 10x Genomics (TXG.US) The life sciences technology company reported its second-quarter 2026 financial results in early August 2026. Earlier, in June 2026, 10x Genomics completed the acquisition of Proteintech Genomics to further expand its platform reach in single-cell and spatial biology research. Management is working to integrate the newly acquired business lines to solidify its penetration in the translational research market, according to people familiar with the matter. ### DiDi Global (DIDIY.US) DiDi Global continues to operate its mobility technology platform encompassing ride-hailing, designated driving, and intra-city freight services. Beyond its core operations in China, the company is pushing forward with its international ride-hailing and food delivery services. As macro mobility data recovers, the market remains focused on the rebound in order volumes and the profitability of its various initiatives. ### Kioxia (KXIAY.US) Kioxia, focused on NAND flash memory, holds a critical position in the global market. Data shows the company ranked as the third-largest NAND vendor globally with a 14% market share as of 2024. Amid evolving storage demands for PCs and enterprise servers, the firm's shipment volumes of solid-state drives and flash products are directly influenced by supply chain capacity cycles. ### Direxion Daily Gold Miners Index Bear 2X Shares (DUST.US) The fund aims to provide two times the inverse daily performance of the NYSE Arca Gold Miners Index. Amid recent heightened volatility in gold mining stocks, this inverse tool has become a target for some institutions seeking to hedge against downside risks in the precious metals cycle. Its net asset value performance maintains a strict inverse leveraged relationship with the underlying mining equities. On the capital flow and operational expansion front, these equities are showing pronounced sector divergence, with biotech pipeline advancements running parallel to hardware manufacturers' battle for market share, as institutional investors reassess their exposure to these niche assets, according to people familiar with the matter. *This article does not constitute investment advice.* ### Related Stocks - [FLY.US](https://longbridge.com/en/quote/FLY.US.md) - [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md) - [SBSW.US](https://longbridge.com/en/quote/SBSW.US.md) - [TXG.US](https://longbridge.com/en/quote/TXG.US.md) - [DIDIY.US](https://longbridge.com/en/quote/DIDIY.US.md) - [KXIAY.US](https://longbridge.com/en/quote/KXIAY.US.md) ## Related News & Research - [How Investors Are Reacting To DiDi Global (DIDI.Y) Returning To Quarterly Profit Amid First-Half Loss](https://longbridge.com/en/news/296706548.md) - [Arcturus Therapeutics to Present ARCT-810 Data on OTC Deficiency at 2026 Symposium](https://longbridge.com/en/news/296895406.md) - [More ride-hailing firms target Hong Kong amid licensing roll-out, Mable Chan says](https://longbridge.com/en/news/296695865.md) - [Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)](https://longbridge.com/en/news/297041490.md) - [10x Genomics director Sarah A. Teichmann disposes of USD 433,106 in common shares](https://longbridge.com/en/news/296141275.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**